- Global Blood Therapeutics is creating a juggernaut blood therapeutics portfolio that could make them the standard bearer in sickle cell disease.
- Unfortunately, the share price has been sinking along with the rest of the sector, but the recent Q2 earnings beat might change that.
- The company continues to move its pipeline forward and has submitted its sNDA for Oxbryta for SCD in children 2-11 years of age. In addition, the company is looking for.
- I discuss my strategy for managing my GBT position as we wait for the inflection.
For further details see:
Global Blood Therapeutics: Attempting To Classify The Investment